Disulfide stabilization of human norovirus GI.1 virus-like particles focuses immune response toward blockade epitopes

Abstract Human noroviruses are non-enveloped, single-strand RNA viruses that cause pandemic outbreaks of acute gastroenteritis. A bivalent vaccine containing GI.1 and GII.4 virus-like particles (VLPs) has been shown to be safe and highly immunogenic, but its efficacy and durability have been limited...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Raffaello Verardi, Lisa C. Lindesmith, Yaroslav Tsybovsky, Jason Gorman, Gwo-Yu Chuang, Caitlin E. Edwards, Paul D. Brewer-Jensen, Michael L. Mallory, Li Ou, Arne Schön, Wei Shi, Ena S. Tully, George Georgiou, Ralph S. Baric, Peter D. Kwong
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Acceso en línea:https://doaj.org/article/291f486fe191490c902890335db78af5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract Human noroviruses are non-enveloped, single-strand RNA viruses that cause pandemic outbreaks of acute gastroenteritis. A bivalent vaccine containing GI.1 and GII.4 virus-like particles (VLPs) has been shown to be safe and highly immunogenic, but its efficacy and durability have been limited. Here, we show that norovirus GI.1 VLPs are unstable and contain a substantial fraction of dissociated VLP components. Broadly reactive, non-neutralizing antibodies isolated from vaccinated donors bound to the dissociated components, but not to the intact VLPs. Engineering of interprotomer disulfide bonds within the shell domain prevented disassembly of the VLPs, while preserving antibody accessibility to blockade epitopes. Without adjuvant, mice immunized with stabilized GI.1 VLPs developed faster blockade antibody titers compared to immunization with wild-type GI.1 VLPs. In addition, immunization with stabilized particles focused immune responses toward surface-exposed epitopes and away from occluded epitopes. Overall, disulfide-stabilized norovirus GI.1 VLPs elicited improved responses over the non-disulfide-stabilized version, suggesting their promise as candidate vaccines.